MediPharm Labs Corp.
MediPharm Labs Corp. (LABS.TO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
labs.to · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for MediPharm Labs Corp. (LABS.TO) measures how much investors pay for each dollar of the company's trailing earnings. LABS.TO's current PE ratio of N/A is calculated by dividing its stock price of $0.07 by its TTM earnings per share of -$0.02.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2016 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
MediPharm Labs Corp.You LABS.TO | $32M | N/A | — | -$0.02 |
 DIAGNOS Inc. ADK.V | $22M | N/A | — | -$0.05 |
 Avicanna Inc. AVCN.TO | $14M | N/A | — | -$0.02 |
 Charlotte's Web Holdings, Inc. CWEB.TO | $92M | N/A | — | -$0.19 |
 Gemina Laboratories Ltd. GLAB.CN | $5M | N/A | — | -$0.06 |
 Greenway Greenhouse Cannabis Corporation GWAY.CN | $21M | N/A | — | -$0.02 |
 Izotropic Corporation IZO.CN | $19M | N/A | — | -$0.05 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.02 | — | |
2024-12-31 FY2024 | — | $-0.03 | — | |
2023-12-31 FY2023 | — | $-0.04 | — | |
2022-12-31 FY2022 | — | $-0.11 | — | |
2021-12-31 FY2021 | — | $-0.22 | — | |
2020-12-31 FY2020 | — | $-0.48 | — | |
2019-12-31 FY2019 | 409.55x | $0.01 | — | |
2018-12-31 FY2018 | — | $-0.12 | — | |
2017-12-31 FY2017 | — | $-0.20 | — | |
2016-12-31 FY2016 | — | $-0.07 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for MediPharm Labs Corp. (LABS.TO) measures how much investors pay for each dollar of the company's trailing earnings. LABS.TO's current PE ratio of N/A is calculated by dividing its stock price of $0.07 by its TTM earnings per share of -$0.02.
Frequently asked questions
LABS.TO pe ratio · 6 questionsLABS.TO's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.07 and TTM EPS of -$0.02. Data sourced from Financial Modeling Prep via LABS.TO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · MediPharm Labs Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08